GlassScriptPhysician profile
Tam T Ly
NPI 1992858443
$1,819.91
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $278 · 2021: $553 · 2022: $548 · 2023: $65.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $488.57 | 2019-2022 | |
| Smith+Nephew, INC. | $195.95 | 2019-2021 | |
| Gilead Sciences, INC. | $125.49 | 2019-2022 | |
| Mdd US Operations, LLC | $118.94 | 2022-2023 | Gocovri |
| Lundbeck LLC | $114.89 | 2021-2022 | |
| Melinta Therapeutics, LLC | $96.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.62 | 2019-2021 | |
| Sk Life Science, INC. | $76.57 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $70.18 | 2020-2021 | |
| Abbvie INC. | $68.88 | 2022 | |
| Vyera Pharmaceuticals, LLC | $39.87 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $38.85 | 2020 | |
| Janssen Biotech, INC. | $34.24 | 2021-2022 | |
| Lilly USA, LLC | $30.58 | 2020-2022 | |
| Ucb, INC. | $27.50 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.72 | 2022 | |
| Acera Surgical, INC. | $22.04 | 2021 | |
| Amgen INC. | $21.65 | 2021 | |
| Derma Sciences, INC. | $21.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.46 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.22 | 2019 | |
| Integra Lifesciences Corporation | $16.91 | 2022 | |
| Astellas Pharma US INC | $15.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.78 | 2022 | |
| Adamas Pharmaceuticals, INC. | $14.39 | 2021 | |
| Theratechnologies INC. | $12.61 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tam Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.